Swiss drug major Roche revealed at its R&D day that it has 119 projects in research and 61 New Molecular Entities, including six opt-in opportunities, in development. The company also noted that it has more than 12 products, either already on the market or in late-stage trials, with sales or sales potential of more than 1 billion Swiss francs ($778 million) each.
Oncology
Roche is a leader in the field of oncology and has a broad range of anticancer drugs, including treatments for non-Hodgkin's lymphoma, breast cancer and colorectal cancer. The main products are:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze